DOACs reduce stroke, mortality, and major bleeding risk compared to vitamin K antagonists in hemodialysisDOACs Show Lower Stroke and Bleeding Risk in Dialysis Patients

Cardiology in review Published September 1, 2026 Study authors: Goyal Aman, Maheshwari Surabhi, Fatima Laveeza, Javed Binish, Rathore Sawai Singh, Mahalwar Gauranga PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider DOACs over vitamin K antagonists for atrial fibrillation in hemodialysis patients to reduce stroke and bleeding.

This meta-analysis evaluates the comparative efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonists for the management of atrial fibrillation in patients undergoing chronic hemodialysis. The analysis synthesized data on several clinical outcomes, including stroke types, mortality, and various bleeding events.

The meta-analysis reported that DOACs were associated with a lower risk of all-cause stroke (RR: 0.64; 95% CI: 0.51-0.81; P = 0.0001) and ischemic stroke (RR: 0.53; 95% CI: 0.29-0.96; P = 0.04). Furthermore, patients in the DOAC group experienced lower rates of all-cause mortality (RR: 0.73; 95% CI: 0.60-0.88; P = 0.001) and major bleeding (RR: 0.63; 95% CI: 0.52-0.76; P < 0.00001). Gastrointestinal bleeding and intracranial hemorrhage were also lower in the DOAC group (RR: 0.67; 95% CI: 0.53-0.85; P = 0.0009 and RR: 0.57; 95% CI: 0.38-0.84; P = 0.004, respectively).

No significant differences were observed between DOACs and vitamin K antagonists regarding cardiovascular-related death (RR: 1.34; 95% CI: 0.69-2.60; P = 0.39), clinically relevant nonmajor bleeding (RR: 0.90; 95% CI: 0.75-1.08; P = 0.26), or hemorrhagic stroke (RR: 0.36; 95% CI: 0.06-2.24; P = 0.28). Specific limitations and certainty of evidence were not reported in the source.

How this fits prior evidence

This meta-analysis addresses a gap in the management of atrial fibrillation in specific populations, specifically those undergoing chronic hemodialysis. While prior evidence notes that POAF is associated with increased long-term thromboembolic risk following isolated valve surgery, this study provides specific comparative data for DOACs versus vitamin K antagonists in the hemodialysis population. It confirms the utility of DOACs as a potentially safer alternative for stroke and bleeding prevention in this high-risk cohort.

Researchers analyzed data regarding patients with atrial fibrillation who are undergoing chronic hemodialysis. The study compared two types of blood thinners: direct oral anticoagulants (DOACs) and vitamin K antagonists. This comparison is important because managing blood clots and bleeding risks is a complex challenge for patients with kidney issues.

The findings showed that patients taking DOACs had a lower risk of all-cause stroke and ischemic stroke compared to those on vitamin K antagonists. Additionally, the DOAC group showed lower rates of all-cause mortality and major bleeding. Specific types of bleeding, such as gastrointestinal bleeding and intracranial hemorrhage, were also lower in the group taking DOACs.

While the results for several types of bleeding and death were positive for those on DOACs, some outcomes like cardiovascular-related death and hemorrhagic stroke did not show a significant difference between the two treatments. Because this is a meta-analysis of existing data, the results provide a broad overview but do not replace a doctor's specific medical advice for individual treatment plans.

What this means for you:

DOACs were linked to lower stroke and bleeding risks in patients with atrial fibrillation on hemodialysis.

Common questions

What are the benefits of using DOACs for dialysis patients?

For patients with atrial fibrillation on hemodialysis, the study found that DOACs were linked to a lower risk of all-cause stroke, ischemic stroke, and all-cause mortality. The data also showed a lower risk of major bleeding, gastrointestinal bleeding, and intracranial hemorrhage compared to vitamin K antagonists.

Are DOACs safer than vitamin K antagonists for these patients?

The study showed that the DOAC group had a lower risk of major bleeding (RR: 0.63) and gastrointestinal bleeding (RR: 0.67) than the vitamin K antagonist group. However, there was no significant difference found between the two groups regarding cardiovascular-related death or hemorrhagic stroke.

Who specifically is this finding for?

This finding specifically concerns patients who have atrial fibrillation and are undergoing chronic hemodialysis. Because every patient's health situation is unique, you should talk to your doctor to determine which blood thinner is safest and most effective for your specific needs.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PMID38990003

View Original Abstract ↓

This meta-analysis aimed to assess the outcomes of patients with atrial fibrillation undergoing chronic hemodialysis, comparing the effectiveness of direct oral anticoagulants (DOACs) and vitamin K antagonists. A systematic search was conducted across various databases including PubMed, Embase, and Google Scholar. Efficacy outcomes focused on the risk of stroke and mortality, whereas safety outcomes assessed the risk of bleeding. Review Manager generated forest plots for data synthesis. Statistical significance was set at P < 0.05, and random-effects models were used. Subgroup analysis identified the sources of heterogeneity. Nine studies met the inclusion criteria for the final analysis. The risk of all-cause stroke [risk ratio (RR): 0.64; 95% confidence interval (CI): 0.51-0.81; P = 0.0001; I2 = 0%], ischemic stroke (RR: 0.53; 95% CI: 0.29-0.96; P = 0.04; I2 = 0%), all-cause mortality (RR: 0.73; 95% CI: 0.60-0.88; P = 0.001; I2 = 71%), major bleeding (RR: 0.63; 95% CI: 0.52-0.76; P < 0.00001; I2 = 44%), gastrointestinal bleeding (RR: 0.67; 95% CI: 0.53-0.85; P = 0.0009; I2 = 36%), intracranial hemorrhage (RR: 0.57; 95% CI: 0.38-0.84; P = 0.004; I2 = 0%) were lower in the DOAC group compared with the vitamin K antagonist group. The risk of cardiovascular-related death (RR: 1.34; 95% CI: 0.69-2.60; P = 0.39; I2 = 0%), clinically relevant nonmajor bleeding (RR: 0.90; 95% CI: 0.75-1.08; P = 0.26; I2 = 28%), and hemorrhagic stroke (RR: 0.36; 95% CI: 0.06-2.24; P = 0.28; I2 = 10%) showed no significant differences. In conclusion, the risks of all-cause stroke, ischemic stroke, all-cause mortality, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage in patients with atrial fibrillation undergoing chronic hemodialysis were lower in the DOAC group.

DOACs reduce stroke, mortality, and major bleeding risk compared to vitamin K antagonists in hemodialysisDOACs Show Lower Stroke and Bleeding Risk in Dialysis Patients

How this fits prior evidence

Common questions

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

DOACs reduce stroke, mortality, and major bleeding risk compared to vitamin K antagonists in hemodialysisDOACs Show Lower Stroke and Bleeding Risk in Dialysis Patients

How this fits prior evidence

Common questions

More on Atrial Fibrillation

Study Details

Dual antiplatelet therapy reduces all-cause death but not MACE or myocardial infarction in MINOCA

Dual antiplatelet therapy shows survival benefits for MINOCA patients

Clinical research that matters. Delivered to your inbox.

Related in Cardiology

From Other Specialties